Diana L Blithe

No ORCID on file · 5 papers in corpus
rct 2022
Contraception ·doi:10.1016/j.contraception.2022.04.002

OBJECTIVES: To describe ovulation inhibition and safety of daily oral ulipristal acetate (UPA) over 84 days. STUDY DESIGN: This multi-center phase 1 and/or 2 trial randomized participants to use oral ulipristal 10 mg or 5 mg daily or a 3 c…

other 2022
Gates Open Research ·doi:10.12688/gatesopenres.13609.1

Background: Contraceptive-induced menstrual changes (CIMCs) can affect family planning (FP) users' lives in both positive and negative ways, resulting in both opportunities and consequences. Despite this, and despite the important links bet…

other 2008
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc ·doi:10.1038/modpathol.2008.19

Progesterone receptor modulators (PRM) are hormonally active drugs effective in the management of endometriosis and uterine leiomyomata. The endometrial effects of progestin blockade by PRMs in premenopausal women are currently being evalua…

other 2007
Human Reproduction Update ·doi:10.1093/humupd/dmm023

Progesterone receptor modulators (PRMs) have been used for contraceptive research, as well as for treatment of fibroids, endometriosis and heavy or irregular menstrual bleeding. Long-term treatment with these compounds results in changes to…

nonrandomized-trial 2003
Steroids ·doi:10.1016/s0039-128x(03)00118-1

CDB-2914 (17 alpha-acetoxy-11 beta-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione) is a 19-norprogesterone derivative that acts as an antagonist in progesterone-responsive tissues. It binds to progesterone receptors A and B w…